Genomic Biomarkers Market Size, Share & Growth Report | 2030

Name: Growth Market Reports
Address: 500 East E Street, Ontario, 91764, USA
Telephone: +1 909 414 1393

Segments - Global Genomic Biomarkers Market by Applications (Oncology, Cardiovascular Diseases, Neurological Diseases, Renal Disorders, and Others), End-users (Diagnostic & Research Laboratories, Hospitals, and Others), and Regions (Asia Pacific, North America, Europe, Latin America, and Middle East & Africa) Forecasts, 2021-2028

Author : Raksha Sharma

Fact-checked by : V. Chandola

Editor : Vishal Golekar

Report Description
Segments
Table Of Content
Methodology
Related Reports

Customize This Report

Ask for Research To Be Focused On Specific Regions or Segments
Receive Data As Per Your Format and Definition
Companies Profiled based on Your Requirements
Breaking Down Competitive Landscape as per Your Requirements
Any Level of Customization

Request for Customization

Get free sample report Speak With Analyst Purchase Premium Report

Growth Market Report Certified By

Quick Contact

+1 909 414 1393

sales@growthmarketreports.com

Report Description

The Global Genomic Biomarkers Market is estimated to expand at a substantial CAGR during the forecast period, 2021-2028. Genomic biomarkers are measurable Deoxyribonucleic acid (DNA) and Ribonucleic acid (RNA) characteristics, which act as indicators of diagnosis, normal biologic processes, pathogenic processes and therapy selection. These biomarkers reflect disease susceptibility, disease expression, and disease outcome or other intervention. Easily detection of variants in the DNA code, genomic biomarkers facilitate early discovery of diseases by predicting its possibility and enhances patient care by monitoring the outcomes.

Genomic Biomarkers Market Trends, Drivers, Restraints, and Opportunities:

The increasing affliction of chronic diseases such as cardiovascular diseases, cancer, strokes, and arthritis is attributed to the growing genomic biomarkers market. As per the estimation by the World Health Organization in 2018, around 16% of deaths around the world are caused due to cancer trailed by cardiovascular diseases.
Soaring demand for marginally invasive procedures and technological progressions are anticipated to increase in the demand for genomic biomarkers.
Huge costs, complicated development process, strict government policies, and lack of uniform means to validate the products of manufacturers can restraint the growth of the genomic biomarkers market during the forecast period.
Progressing R&D and the development of advanced infrastructure that allows data sharing along with the call for individualized medicines are expected to propel the further development of the market during the forecast period.

Scope of the Genomic Biomarkers Market Report:

The report on the global genomic biomarkers market includes an assessment of the market, size, share, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Attributes	Details
Base Year	2020
Historic Data	2018 & 2019
Forecast Period	2021–2028
Regional Scope	Asia Pacific, North America, Europe, Latin America, and Middle East & Africa
Report Coverage	Market scope, analysis, share, competitive analysis, growth facts, restraints, opportunities, and revenue forecast

Global Genomic Biomarkers Market Segment Insights:

Global Genomic Biomarkers Market Outlook

Oncology Segment is Expected to Dominate the Market
On the basis of applications, the global genomic biomarkers market can be segmented into oncology, cardiovascular diseases, neurological diseases, renal disorders, and others. The oncology segment is estimated to dominate the market during the forecast period. The growth of the segment is owing to the predominance use of the devices for various applications related to types of cancers such as prostate, breast, and lung cancer. Moreover, push-in target therapies along with technological improvements and dependability on oncology biomarkers is estimated to drive the growth of the segment during the forecast period. Increasing unhealthy lifestyle and wide culture of smoking have prompted biopharmaceutical companies to prioritize the expansion of oncology products such as genomic biomarkers.

Diagnostic & Research Laboratories to occupy significant market share
In terms of end users, the global genomic biomarkers market can be divided into diagnostic & research laboratories, hospitals, and others. The diagnostic & research laboratories segment is anticipated to account for a significant market share due to increase in number of patients who adopt genomic biomarkers for various diagnostic and research purposes.

North America constitutes a large share of the global market
Based on regions, the global genomic biomarkers market can be classified as North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market in North America accounted for a prime share in terms of revenue and is anticipated to retain its position during the forecast period. Some of the key reasons pushing the market growth in the region can be attributed to advanced healthcare facilities, encouraging government policies, and vast research funds. Activities in extensive R&D activities, cutting-edge technologies, and significant funding by governments along with private players especially in the US is projected to exhibit of the regional market growth during the forecast period.

Segments

Segments Covered in the Report
The global genomic biomarkers market can be divided based on components, delivery modes, functions, end users and regions.

Applications

Oncology
Cardiovascular Diseases
Neurological Diseases
Renal Disorders
Others

End-Users

Diagnostic & Research Laboratories
Hospitals
Others

Regions

North America
Europe
Latin America
Asia Pacific
Middle East & Africa

Key Players

Alma Group
Beckman Coulter Inc.
Bio-Rad Laboratories Inc.
CENTOGENE N.V.
Euro fins Scientific
QIAGEN
GENOME LIFE SCIENCES
Hoffmann-La Roche Ltd.
Myriad Genetics Inc.
Sema4
Thermo Fisher Scientific Inc.

Competitive Landscape

The genomic biomarkers market is extremely competitive due to the huge number of competitors. Major players in the global genomic biomarkers market include Alma Group, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., CENTOGENE N.V., Euro fins Scientific, QIAGEN, GENOME LIFE SCIENCES, Hoffmann-La Roche Ltd, Myriad Genetics, Inc, Sema4, and Thermo Fisher Scientific Inc.

Many companies have adopted research and development as a tool to withstand the competition along with expansions, joint ventures, acquisitions, and others to increase their market share. The strategy will help to provide better quality and new features to customers.

Table Of Content

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Genomic Biomarkers Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Genomic Biomarkers Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Genomic Biomarkers Market - Supply Chain
  4.5. Global Genomic Biomarkers Market Forecast
     4.5.1. Genomic Biomarkers Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Genomic Biomarkers Market Size (000â€™ Units) and Y-o-Y Growth
     4.5.3. Genomic Biomarkers Market Absolute $ Opportunity
5. Global Genomic Biomarkers Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Genomic Biomarkers Market Size and Volume Forecast by Applications
     5.3.1. Oncology
     5.3.2. Cardiovascular Diseases
     5.3.3. Neurological Diseases
     5.3.4. Renal Disorders
     5.3.5. Others
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Genomic Biomarkers Market Analysis and Forecast by End Users
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by End Users
     6.2.2. Y-o-Y Growth Projections by End Users
  6.3. Genomic Biomarkers Market Size and Volume Forecast by End Users
     6.3.1. Diagnostic & Research Laboratories
     6.3.2. Hospitals
     6.3.3. Others
  6.4. Absolute $ Opportunity Assessment by End Users
  6.5. Market Attractiveness/Growth Potential Analysis by End Users
7. Global Genomic Biomarkers Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Genomic Biomarkers Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Genomic Biomarkers Demand Share Forecast, 2019-2026
8. North America Genomic Biomarkers Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Genomic Biomarkers Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Genomic Biomarkers Market Size and Volume Forecast by Applications
     8.4.1. Oncology
     8.4.2. Cardiovascular Diseases
     8.4.3. Neurological Diseases
     8.4.4. Renal Disorders
     8.4.5. Others
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. North America Genomic Biomarkers Market Size and Volume Forecast by End Users
     8.7.1. Diagnostic & Research Laboratories
     8.7.2. Hospitals
     8.7.3. Others
  8.8. Basis Point Share (BPS) Analysis by End Users
  8.9. Y-o-Y Growth Projections by End Users
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Genomic Biomarkers Demand Share Forecast, 2019-2026
9. Latin America Genomic Biomarkers Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Genomic Biomarkers Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Genomic Biomarkers Market Size and Volume Forecast by Applications
     9.4.1. Oncology
     9.4.2. Cardiovascular Diseases
     9.4.3. Neurological Diseases
     9.4.4. Renal Disorders
     9.4.5. Others
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Latin America Genomic Biomarkers Market Size and Volume Forecast by End Users
     9.7.1. Diagnostic & Research Laboratories
     9.7.2. Hospitals
     9.7.3. Others
  9.8. Basis Point Share (BPS) Analysis by End Users
  9.9. Y-o-Y Growth Projections by End Users
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Genomic Biomarkers Demand Share Forecast, 2019-2026
10. Europe Genomic Biomarkers Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Genomic Biomarkers Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Genomic Biomarkers Market Size and Volume Forecast by Applications
     10.4.1. Oncology
     10.4.2. Cardiovascular Diseases
     10.4.3. Neurological Diseases
     10.4.4. Renal Disorders
     10.4.5. Others
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Europe Genomic Biomarkers Market Size and Volume Forecast by End Users
     10.7.1. Diagnostic & Research Laboratories
     10.7.2. Hospitals
     10.7.3. Others
  10.8. Basis Point Share (BPS) Analysis by End Users
  10.9. Y-o-Y Growth Projections by End Users
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Genomic Biomarkers Demand Share Forecast, 2019-2026
11. Asia Pacific Genomic Biomarkers Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Genomic Biomarkers Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Genomic Biomarkers Market Size and Volume Forecast by Applications
     11.4.1. Oncology
     11.4.2. Cardiovascular Diseases
     11.4.3. Neurological Diseases
     11.4.4. Renal Disorders
     11.4.5. Others
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Asia Pacific Genomic Biomarkers Market Size and Volume Forecast by End Users
     11.7.1. Diagnostic & Research Laboratories
     11.7.2. Hospitals
     11.7.3. Others
  11.8. Basis Point Share (BPS) Analysis by End Users
  11.9. Y-o-Y Growth Projections by End Users
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Genomic Biomarkers Demand Share Forecast, 2019-2026
12. Middle East & Africa Genomic Biomarkers Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Genomic Biomarkers Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Genomic Biomarkers Market Size and Volume Forecast by Applications
     12.4.1. Oncology
     12.4.2. Cardiovascular Diseases
     12.4.3. Neurological Diseases
     12.4.4. Renal Disorders
     12.4.5. Others
  12.5. Basis Point Share (BPS) Analysis by Applications
  12.6. Y-o-Y Growth Projections by Applications
  12.7. Middle East & Africa Genomic Biomarkers Market Size and Volume Forecast by End Users
     12.7.1. Diagnostic & Research Laboratories
     12.7.2. Hospitals
     12.7.3. Others
  12.8. Basis Point Share (BPS) Analysis by End Users
  12.9. Y-o-Y Growth Projections by End Users
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Genomic Biomarkers Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Genomic Biomarkers Market: Market Share Analysis
  13.2. Genomic Biomarkers Distributors and Customers
  13.3. Genomic Biomarkers Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Alma Group
     13.4.2. Beckman Coulter Inc.
     13.4.3. Bio-Rad Laboratories Inc.
     13.4.4. CENTOGENE N.V.
     13.4.5. Euro fins Scientific
     13.4.6. QIAGEN
     13.4.7. GENOME LIFE SCIENCES
     13.4.8. Hoffmann-La Roche Ltd.